# Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis

> **NCT02308670** · — · COMPLETED · sponsor: **University at Buffalo** · enrollment: 150 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02308670
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2016-10-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02308670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02308670, "Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02308670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*